109 related articles for article (PubMed ID: 394865)
1. Use of VM-26 as a single agent in the treatment of renal carcinoma.
Hire EA; Samson MK; Fraile RJ; Baker LH
Cancer Clin Trials; 1979; 2(4):293-5. PubMed ID: 394865
[TBL] [Abstract][Full Text] [Related]
2. Treatment of small cell bronchogenic carcinoma with VM-26.
Woods RL; Fox RM; Tattersall MH
Cancer Treat Rep; 1979; 63(11-12):2011-3. PubMed ID: 230897
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of bone marrow toxicity of VM-26-CCNU combination by bleomycin.
Hildebrand J; Gangji D; Nouwynck C; Machin D
Cancer Treat Rep; 1977 Dec; 61(9):1695-8. PubMed ID: 74284
[No Abstract] [Full Text] [Related]
4. Teniposide in the treatment of non-small cell lung carcinoma.
Giaccone G; Donadio M; Ferrati P; Bonardi G; Ciuffreda L; Bagatella M; Calciati A
Cancer Treat Rep; 1987 Jan; 71(1):83-5. PubMed ID: 3024829
[TBL] [Abstract][Full Text] [Related]
5. Combination VM-26 and adriamycin for metastatic transitional cell carcinoma.
Rodriguez LH; Johnson DE; Holoye PY; Samuels ML
Cancer Treat Rep; 1977; 61(1):87-8. PubMed ID: 324624
[No Abstract] [Full Text] [Related]
6. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
Bleyer WA; Krivit W; Chard RL; Hammond D
Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803
[TBL] [Abstract][Full Text] [Related]
7. Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.
Oishi N; Berenberg J; Blumenstein BA; Johnson K; Rivkin SE; Bukowski RM; O'Bryan RM; Stephens RL; Quagliana J; Saiers JH
Cancer Treat Rep; 1987 Dec; 71(12):1307-8. PubMed ID: 3690547
[No Abstract] [Full Text] [Related]
8. Phase II trial of VM-26 in patients with metastatic malignant melanoma.
Bellet RE; Catalno RB; Mastrangelo MJ; Berd D; Koons LS
Cancer Treat Rep; 1978 Mar; 62(3):445-7. PubMed ID: 348313
[No Abstract] [Full Text] [Related]
9. High-dose teniposide for refractory malignancies: a phase I study.
de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
Qazi R; Elson P; Khandekar JD
Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
[No Abstract] [Full Text] [Related]
11. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.
Rivera G; Green A; Hayes A; Avery T; Pratt C
Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of VM-26 in adult malignancies.
Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
[No Abstract] [Full Text] [Related]
13. Preliminary evaluation of VM-26: a new epipodophyllotoxin derivative, in the treatment of urogenital tumours.
Pavone-Macaluso M; Caramia G; Rizzo FP; Messana V
Eur Urol; 1975; 1(1):53-6. PubMed ID: 786645
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of teniposide in small cell carcinoma of the lung.
Pedersen AG; Bork E; Osterlind K; Dombernowsky P; Hansen HH
Cancer Treat Rep; 1984 Oct; 68(10):1289-91. PubMed ID: 6098366
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors.
Seiler RW; Vassella F; Markwalder H
Surg Neurol; 1979 Mar; 11(3):237-42. PubMed ID: 473022
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of teniposide (VM-26) in multiple myeloma.
Tirelli U; Carbone A; Zagonei V; Brema F; Veronesi A; Grigoletto E; Volpe R
Am J Clin Oncol; 1985 Aug; 8(4):329-31. PubMed ID: 3909805
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.
Hahn RG; Bauer M; Wolter J; Creech R; Bennett JM; Wampler G
Cancer Treat Rep; 1979 Mar; 63(3):513-5. PubMed ID: 371804
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26.
Gad-el-Mawla NM; Muggia FM; Hamza MR; El-Morsi B; Sherif M; Mansour MA; Khafagy M; El-Sebai IT
Cancer Treat Rep; 1978 Jul; 62(7):993-6. PubMed ID: 99234
[No Abstract] [Full Text] [Related]
19. [Use of VM-26 as a single agent in the treatment of transitional cell carcinoma of the urinary tract].
Aso Y; Ushiyama T; Suzuki K; Tajima A; Naide Y; Ohshima S; Matsuura O; Fukushima M; Ota K; Ono Y
Nihon Gan Chiryo Gakkai Shi; 1988 May; 23(5):1046-51. PubMed ID: 3418215
[No Abstract] [Full Text] [Related]
20. Phase II trial of VP-16-213 in non-small-cell lung cancer.
Itri LM; Gralla RJ; Chapman RA; Kelsen DP; Casper ES; Golbey RB
Am J Clin Oncol; 1982 Feb; 5(1):45-7. PubMed ID: 7081137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
